Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Musculoskeletal  |  Nephrology  |  Rheumatology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Gout (Hyperuricemia) Clinical Trials

A listing of Gout (Hyperuricemia) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (12) clinical trials

Qualified participants will receive: Study-related medication at no cost Study-related medical exams at no cost Compensation for time and travel  

Phase N/A

Regulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic Treatments

B cells are known to play an important role in auto-immune diseases by activating T cells, secreting inflammatory cytokines and autoreactive antibodies. However, a sub-type of B cells named regulatory B cells or Bregs has recently shown capacities to prevent or cure arthritis in mouse models. Bregs have also been …

Phase N/A

A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout

This study will assess the serum uric acid lowering effects and safety of SHR4640 compared to placebo and Allopurinol in patients with gout


Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)

Gout presents as intermittent acute painful and debilitating gout flares. High serum uric acid levels lead to the deposition of urate crystals in and around the joints, most commonly the big toe (also called podagra) and other peripheral joints. An acute gout flare causes extreme pain and inflammation of the …


Study of KRYSTEXXA (Pegloticase) Plus Methotrexate in Patients With Uncontrolled Gout

This study is a Phase 4, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of pegloticase with MTX vs. pegloticase with placebo for MTX in adult participants with uncontrolled gout.


A Nurse Led Patient Management Programme to Improve Outcomes in Gout

There is evidence from other chronic diseases that nurse led care in addition to standard of care ameliorates outcomes. In gout the primary target is the serum uric acid level (SUA). We intend to demonstrate the superiority of a structured nurse led patient management programme over standard of care in …

Phase N/A

Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout

Gout is an autoinflammatory disease characterized by flares of painful joint inflammation. This inflammation occurs in response to uric acid that crystallizes. After a gout attack, patients usually enter a period that is accompanied by low grade inflammation but is otherwise relatively asymptomatic. Gout is typically associated with certain markers, …

Phase N/A

Effect of a New BI-specifiC Antibody Towards Dendritic Cells on Inflammation in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is one of the most common autoimmune disease in adult. It exists several drugs but none target dendritic cells even if it seems they play a major role in the physiopathology. One of the unit of research of Tours recently develop a new format of bispecific antibody …

Phase N/A

Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions

A recently published clinical trial with zoledronic acid failed to show an effect in improving bone erosions among individuals with chronic tophaceous gout, despite improvements in bone mineral density (BMD) and bone turnover markers. However, it is known that increased numbers of osteoclasts (cells that absorb bone tissue during growth …


Identification of New Biomarkers to Promote Personalized Treatment of Patients With Inflammatory Rheumatic Diseases

Introduction: The medical treatment of inflammatory rheumatic diseases has improved dramatically during the last decades primarily due to the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). However, bDMARD treatment failure occurs in 30-40% of patients due to lack of effectiveness or side effects. The tools to predict treatment outcomes …

Phase N/A